^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    1d
    PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov)
    P3, N=158, Completed, AiCuris Anti-infective Cures AG | Active, not recruiting --> Completed
    Trial completion
    |
    Zyclara (imiquimod)
    1d
    A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions. (clinicaltrials.gov)
    P=N/A, N=99000, Active, not recruiting, Pfizer
    New trial • Real-world evidence
    9d
    A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19. (clinicaltrials.gov)
    P=N/A, N=8252912, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    13d
    A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (clinicaltrials.gov)
    P1, N=165, Completed, Aligos Therapeutics | Active, not recruiting --> Completed
    Trial completion • First-in-human
    13d
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Completed, GemVax & Kael | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    13d
    PanoramicNOR: PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (clinicaltrials.gov)
    P3, N=2000, Active, not recruiting, Haukeland University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2024 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    13d
    A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov)
    P1, N=18, Completed, Vigonvita Life Sciences | Not yet recruiting --> Completed
    Trial completion
    15d
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=59, Completed, GemVax & Kael | Recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    1m
    Therapeutic effects of telomerase-derived peptide GV1001 in experimental autoimmune encephalomyelitis: Inhibiting neuroinflammation and promoting remyelination. (PubMed, Biochem Pharmacol)
    Co-culture assays confirmed that GV1001 blunts microglial neurotoxicity and facilitates remyelination during inflammation. Collectively, the data indicate that GV1001 modulates microglial activity to attenuate neuroinflammation and foster spinal cord repair, underscoring its promise as a multitarget therapy for inflammatory demyelinating diseases such as multiple sclerosis.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • IGF1 (Insulin-like growth factor 1) • PRMT1 (Protein Arginine Methyltransferase 1)
    |
    LucaVax (tertomotide)
    1m
    The impact of continuous renal replacement therapy on the pharmacokinetics of eravacycline in patients with sepsis caused by CRAB/CRE infection: a prospective observational study (ChiCTR2500110877)
    P=N/A, N=20, Not yet recruiting, Beijing Shijitan Hospital, Capital Medical University; Beijing Shijitan Hospital, Capital Medical University
    New trial
    1m
    Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Antiva Biosciences | Trial primary completion date: May 2025 --> Oct 2025
    Trial primary completion date
    1m
    Uncovering Anticancer Mechanisms of Spiramycin Derivatives Using Transcriptomic and Metabolomic Analyses. (PubMed, Metabolites)
    Background: Carrimycin is a mixture of spiramycin derivatives with antibacterial functions... h-SPM reduced the protein level of NR1D1, disrupted metabolic regulation, accumulating ceramide, and the subsequent increased ROS generation promoted apoptosis and pro-inflammatory-like response of cells. Our findings unveiled the anticancer mechanism of a potent anticancer derivative of spiramycin and unveiled its mechanism of action.
    Journal • Metabolomic study
    |
    NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
    |
    carrimycin